Healthcare Investment Banking
The right partner to realize your vision
Delivering best-in-class services to help you achieve your goals. We cultivate tailored solutions that serve client interests first and foremost. Instead of leading with what's best for us, we start with what matters to you. Our experienced team of industry experts is committed to identifying and delivering strategic growth opportunities, exit solutions and the access to capital to maximize shareholder value.
Med-Tech M&A financial advisor*
Private capital raised
Managing directors with 20+ years average experience
No. 1 Med-Tech M&A financial advisor
Piper Sandler ranks number one in Med-Tech M&A advisories by number of sell-side deals, cross border deals and buy-side deals.* The firm is the leading Med-Tech equity bookrunner and has an accomplished Med-Tech research team.**
Industry leading team for 20 years
Piper Sandler has built a leading healthcare services practice over the past 20 years focused on payors and providers. Our team has provided advisory services to many of the top 100 largest healthcare systems in the U.S. and has completed more than 60 transactions since 2015.
Tools and Diagnostics
Dedicated subject matter expertise
Piper Sandler has been actively focused on the tools and diagnostics sector for the last 20+ years with the ability to service companies related to debt, public equity, private placements and M&A/advisory.
Largest dedicated team on Wall Street
Piper Sandler has one of the largest dedicated information-driven healthcare teams on Wall Street with nearly 20 total professionals. Since 2012, the team has completed more than 100 transactions within this sector.
250+ active bookrun deals since 2013
Piper Sandler services a full array of biopharma clients, from early stage biotech to large-cap pharma companies to specialty pharma companies across all therapeutic areas. In addition to capital markets and M&A advisory services, the firm has a leading biopharma equity research team with more than 115 companies under coverage. See the Bioinsights page to learn more.
Upcoming Conferences & Events
Biopharma Mogul Summit
Spring Biopharma Symposium
* Deals above $50M with disclosed advisors **As of 9/15/2020; full credit to each manager, follow-ons include bought deals, includes all deals greater then $20M since 2004
Source: SDC, Dealogic, MergerMarket, Piper Sandler